Aug. 29 at 10:03 PM
$GLSI
My guess is they show data at: SABCS
Previously - data from their completed Phase IIb clinical trial at San Antonio Breast Cancer Symposium (SABCS):
Presented at SABCS 2020. The final 5-year efficacy analysis, including Kaplan-Meier disease-free survival curves showing 100% survival (0% breast cancer recurrences, p=0.0338) in HER2/neu 3+ patients treated with GP2 + GM-CSF who completed the primary immunization series, compared to 89.4% in the placebo arm.
They also presented further analysis of the same Phase IIb data, including immune response and its relationship to recurrence, at SABCS 2021. Earlier Phase I data from prior trials was referenced in company materials.
These presentations supported the design and initiation of their ongoing Phase III trial (Flamingo-01), with posters on the trial design shared at SABCS 2020 and 2021.
